RESUMO
Axions and axionlike particles are strongly motivated dark-matter candidates that are the subject of many current ground based dark-matter searches. We present first results from the Axion Dark-Matter Birefringent Cavity (ADBC) experiment, which is an optical bow-tie cavity probing the axion-induced birefringence of electromagnetic waves. Our experiment is the first optical axion detector that is tunable and quantum noise limited, making it sensitive to a wide range of axion masses. We have iteratively probed the axion mass ranges 40.9-43.3 neV/c^{2}, 49.3-50.6 neV/c^{2}, and 54.4-56.7 neV/c^{2}, and found no dark-matter signal. On average, we constrain the axionlike particle and photon coupling at the level g_{aγγ}≤1.9×10^{-8} GeV^{-1}. We also present prospects for future axion dark-matter detection experiments using optical cavities.
RESUMO
Optical precision spectroscopy of isotope shifts can be used to test for new forces beyond the standard model, and to determine basic properties of atomic nuclei. We measure isotope shifts on the highly forbidden ^{2}S_{1/2}â^{2}F_{7/2} octupole transition of trapped ^{168,170,172,174,176}Yb ions. When combined with previous measurements in Yb^{+} and very recent measurements in Yb, the data reveal a King plot nonlinearity of up to 240σ. The trends exhibited by experimental data are explained by nuclear density functional theory calculations with the Fayans functional. We also find, with 4.3σ confidence, that there is a second distinct source of nonlinearity, and discuss its possible origin.
RESUMO
In the present scenario, resistance to antibiotics is one of the crucial issues related to public health. Earlier, such resistance to antibiotics was limited to nosocomial infections, but it has now become a common phenomenon. Several factors, like extensive development, overexploitation of antibiotics, excessive application of broad-spectrum drugs, and a shortage of target-oriented antimicrobial drugs, could be attributed to this condition. Nowadays, there is a rise in the occurrence of these drug-resistant pathogens due to the availability of a small number of effective antimicrobial agents. It has been estimated that if new novel drugs are not discovered or formulated, there would be no effective antibiotic available to treat these deadly resistant pathogens by 2050. For this reason, we have to look for the formulation of some new novel drugs or other options or substitutes to treat such multidrug-resistant microorganisms (MDR). The current review focuses on the evolution of the most common multidrug-resistant bacteria and discusses how these bacteria escape the effects of targeted antibiotics and become multidrug resistant. In addition, we also discuss some alternative mechanisms to prevent their infection as well.